On July 19, AstraZeneca (NASDAQ: AZN) announced that it had received approval from China's National Medical Products Administration (NMPA) for its drug Imfinzi. This followed the NMPA's review of positive results from a phase 3 trial. Imfinzi can now be used as a first-line treatment for adults with extensive-stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting